The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol and is being developed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback